Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862624 | 1.00 | KMT2A (0.47) | KMT2ABRD4KDM4EALDH1A1CHRNB2 | |
| SCHEMBL21557465 | 0.88 | KMT2A (0.42) | KMT2ABRD4KDM4EALDH1A1F2 | |
| SCHEMBL1340597 | 0.82 | KMT2A (0.47) | KMT2ABRD4ALDH1A1 | |
| SCHEMBL29443104 | 0.82 | KMT2A (0.47) | KMT2ABRD4ALDH1A1 | |
| SCHEMBL19669833 | 0.81 | ALDH1A1 (0.54) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL29992013 | 0.81 | KMT2A (0.47) | KMT2ABRD4KDM4EALDH1A1PKM | |
| SCHEMBL346652 | 0.80 | DRD2 (0.39) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL345477 | 0.78 | KMT2A (0.41) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL5889366 | 0.78 | KMT2A (0.41) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL8071191 | 0.78 | KMT2A (0.41) | KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-04-29 | — | — | US | disclosed |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-113166084-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-113166085-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2022-04-14 | — | — | US | disclosed |
| CN-113166085-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166084-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| EP-3628666-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628672-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628672-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| CN-110914238-A | Compounds as antibiotics | 安塔比奥公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3601224-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | Antabio SAS (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172423-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ARG1, ELANE, INSR | KMT2A 3582/4885BRD4 1007/4885KDM4E 3775/4885 |
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | KMT2A 3671/4885BRD4 1018/4885KDM4E 3917/4885 |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | KMT2A 825/4885BRD4 1863/4885KDM4E 2060/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | KMT2A 2615/4885BRD4 1651/4885KDM4E 4573/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | KMT2A 825/4885BRD4 1863/4885KDM4E 2060/4885 |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | KMT2A 3671/4885BRD4 1018/4885KDM4E 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.